Find public news by keyword, exact ticker, category and date.
Open a ticker page for its news coverage. The news search below stays a text search.
4 results loaded, newest first. End of these results. The latest changes are still being indexed. Try again shortly for updated results.
Outlook Therapeutics appointed Greg DiPasquale chief commercial officer. He will lead commercialization efforts for LYTENAVA as the company prepares a U.S. launch before the end of 2026.
Dr Reddy's Laboratories (NYSE: RDY ) held its first-quarter earnings conference call on Wednesday. Below is the complete transcript from the call. This content is powered APIs. For comprehensive financial data and transcripts, visit The full earnings call is available at Summary Dr Reddy's Laboratories reported a 5.6%
Outlook Therapeutics said it released third-quarter fiscal 2026 results and hosted a call, while management highlighted FDA approval of Lytenava for wet AMD in the U.S.
Outlook Therapeutics submits regulatory filing with SEC